Radiolabeled antibodies for cancer treatment;Les anticorps radiomarqués pour le traitement des cancers

Medecine/Sciences

Volumn 25, Issue 12, 2009, Pages 1039-1045

  Barbet, Jacques ^a   Chatal, Jean François ^a   Kraeber Bodéré, Françoise ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 74749106733     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200925121039     Document Type: Review

References (44)

1. Sisson J, Shapiro B, Beierwaltes WH, et al. Treatment of malignant pheochromocytoma with a new radiopharmaceutical. Trans Assoc Am Physicians 1983 ; 96 : 209-17.
2. Suresh C, Srivastava L. Investigators review potential of antibodies in cancer detection and therapy. J Nucl Med 1987 ; 28 : 143-7.
3. Buchegger F, Press OW, Delaloye AB, Ketterer N. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma. Oncologist 2008 ; 13 : 657-67.
4. Bellet D, Dangles-Marie V. Anticorps humanisés en thérapeutique. Med Sci (Paris) 2005 ; 21 : 1054-62
5. DeNardo GL, DeNardo SJ, Balhorn R. Systemic radiotherapy can cure lymphoma : a paradigm for other malignancies ? Cancer Biother Radiopharm 2008 ; 23 : 383-97.
6. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993 ; 20 : 75-88.
7. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008 ; 359 : 613-26.
8. Park SI, Press OW. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol 2007 ; 14 : 632-8.
9. Zhang MM, Gopal AK. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol 2008 ; 45 : 118-25.
10. Chatal JF, Kraeber-Bodéré F, Barbet J. Consolidation radioimmunotherapy of follicular lymphoma : a step towards cure ? Eur J Nucl Med Mol Imaging 2008 ; 35 : 1236-9.
11. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008 ; 26 : 5156-64.
12. 18F- fluorodeoxyglucose positron emission tomography. Haematologica 2008 ; 93 : 390-7.
13. Ivanov A, Swann R, Illidge T. New insights into the mechanisms of action of radioimmunotherapy in lymphoma. J Pharm Pharmacol 2008 ; 60 : 987-98.
14. Wheldon TE. The radiobiological basis of total body irradiation. Br J Radiol 1997 ; 70 : 1204-7.
15. Sharkey RM, Karacay H, Chang CH, et al. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 2005 ; 19 : 1064-9.
16. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 2001 ; 98 : 2535-43.
17. Goldenberg DM, Gaffar SA, Bennett SJ, Beach JL. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 1981 ; 41 : 4354-60.
18. 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res 1987 ; 47 : 5672-7.
19. 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model. Int J Cancer 1988 ; 41 : 127-34.
20. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005 ; 46 : S115-27.
21. Hahn O, Stadler W. Sorafenib. Curr Opin Oncol 2006 ; 18 :615-21.
22. 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 2005 ; 23 : 6540-8.
23. 2 fragments. J Clin Invest 1989 ; 83 : 1449-56.
24. Schlom J, Eggensperger D, Colcher D, et al. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992 ; 52 : 1067-72.
25. Nilsson FY, Tolmachev V. Affibody molecules : new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Dev 2007 ; 10 : 167-75.
26. Muyldermans S. Single domain camel antibodies : current status. J Biotechnol 2001 ; 74 : 277-302.
27. Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006 ; 24 : 823-34.
28. Chatal JF, Campion L, Kraeber-Bodéré F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy : a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006 ; 24 : 1705-11.
29. Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 2002 ; 94 : 1373-81.
30. 131I-M-labetuzumab after salvage resection of colorectal liver metastases : comparison of outcome to a contemporaneous control group. Ann Surg Oncol 2007 ; 14 : 2577-90.
31. 2 after resection of liver metastases from colorectal cancer. Clin Cancer Res 2008 ; 14 : 3487-93.
32. Milowsky MI, Nanus DM, Kostakoglu I, et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004 ; 22 : 2522-31.
33. 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005 ; 23 : 4591-601.
34. Novak-Hofer I, Schubiger PA. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur J Nucl Med Mol Imaging 2002 ; 29 : 821-30.
35. Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment : the future is radiant. Bone Marrow Transplant 2005 ; 36 : 1021-6.
36. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy : a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999 ; 93 : 3678-84.
37. Supiot S, Faivre-Chauvet A, Couturier O, et al. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer 2002 ; 94 : 1202-9.
38. Mattes MJ. Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer 2002 ; 94 : 1215-23.
39. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002 ; 100 : 1233-9.
40. 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2008 ; 49 : 30-8.
41. Roboz GJ, Bennett JM, Coleman M, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. Leuk Res 2007 ; 31 : 1141-4.
42. Saphire EO, Parren PW, Pantophlet R, et al. Crystal structure of a neutralizing human IGG against HIV-1 : a template for vaccine design. Science 2001 ; 293 : 1155-9
43. Barbet J, Peltier P, Bardet S, et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med 1998, 39, 1172-8.
44. Flux G, Bardies M, Monsieurs M, et al. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Rhys 2006 ; 16 : 47-59.